Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Gut ; 64(11): 1744-54, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25500202

RESUMEN

OBJECTIVE: The colonic microbiota ferment dietary fibres, producing short chain fatty acids. Recent evidence suggests that the short chain fatty acid propionate may play an important role in appetite regulation. We hypothesised that colonic delivery of propionate would increase peptide YY (PYY) and glucagon like peptide-1 (GLP-1) secretion in humans, and reduce energy intake and weight gain in overweight adults. DESIGN: To investigate whether propionate promotes PYY and GLP-1 secretion, a primary cultured human colonic cell model was developed. To deliver propionate specifically to the colon, we developed a novel inulin-propionate ester. An acute randomised, controlled cross-over study was used to assess the effects of this inulin-propionate ester on energy intake and plasma PYY and GLP-1 concentrations. The long-term effects of inulin-propionate ester on weight gain were subsequently assessed in a randomised, controlled 24-week study involving 60 overweight adults. RESULTS: Propionate significantly stimulated the release of PYY and GLP-1 from human colonic cells. Acute ingestion of 10 g inulin-propionate ester significantly increased postprandial plasma PYY and GLP-1 and reduced energy intake. Over 24 weeks, 10 g/day inulin-propionate ester supplementation significantly reduced weight gain, intra-abdominal adipose tissue distribution, intrahepatocellular lipid content and prevented the deterioration in insulin sensitivity observed in the inulin-control group. CONCLUSIONS: These data demonstrate for the first time that increasing colonic propionate prevents weight gain in overweight adult humans. TRIAL REGISTRATION NUMBER: NCT00750438.


Asunto(s)
Adiposidad/efectos de los fármacos , Regulación del Apetito/efectos de los fármacos , Mantenimiento del Peso Corporal/efectos de los fármacos , Colon/metabolismo , Péptido 1 Similar al Glucagón/metabolismo , Sobrepeso/tratamiento farmacológico , Péptido YY/metabolismo , Propionatos/administración & dosificación , Células Cultivadas , Colon/citología , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Propionatos/farmacología
2.
Br J Clin Pharmacol ; 70(5): 674-81, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21039761

RESUMEN

AIMS: To investigate (i) if kisspeptin administration alters heart rate (HR) or blood pressure (BP) in healthy male and female volunteers, (ii) whether circulating plasma kisspeptin concentrations in healthy pregnant women and women with hypertensive diseases of pregnancy correlate with BP and (iii) whether women with hypertensive diseases of pregnancy have altered plasma kisspeptin concentrations. METHODS: We have previously reported the effects of administration of kisspeptin-54 on gonadotrophin secretion in healthy male and female volunteers. In these studies, cardiovascular parameters were not a primary endpoint. However, data were also collected on BP and HR for 4h post administration of kisspeptin-54. Blood samples were taken from 105 women in the third trimester of pregnancy (27 women with hypertensive diseases of pregnancy and 78 controls). Samples were assayed for plasma kisspeptin immunoreactivity (IR). RESULTS: Administration of kisspeptin was not associated with significant changes in HR or BP in healthy men or women. There was no significant correlation between plasma kisspeptin concentration and BP in healthy pregnant women or in those with hypertensive diseases of pregnancy. No significant differences in plasma kisspeptin-IR concentrations were observed between women with hypertensive diseases of pregnancy and normotensive pregnant controls, plasma kisspeptin concentrations ±SE: controls 2878 ± 157pmol l(-1) ; pregnancy-induced hypertension 2696 ± 299pmoll(-1) (95% CI vs. controls -514, 878pmoll(-1) ); pre-eclampsia 3519 ± 357 (95% CI vs. controls -1644, 362pmoll(-1) ). CONCLUSIONS: Elevation of plasma kisspeptin-IR is not associated with an alteration in BP in humans.


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Hipertensión Inducida en el Embarazo/fisiopatología , Preeclampsia/fisiopatología , Complicaciones Cardiovasculares del Embarazo/fisiopatología , Proteínas Supresoras de Tumor/sangre , Proteínas Supresoras de Tumor/farmacología , Adulto , Estudios de Casos y Controles , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Humanos , Hipertensión Inducida en el Embarazo/sangre , Kisspeptinas , Masculino , Preeclampsia/sangre , Embarazo , Complicaciones Cardiovasculares del Embarazo/sangre , Tercer Trimestre del Embarazo
3.
Nutr Res Rev ; 23(1): 135-45, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20482937

RESUMEN

The way in which the composition of the diet may affect appetite, food intake and body weight is now receiving considerable attention in a bid to halt the global year-on-year rise in obesity prevalence. Epidemiological evidence suggests that populations who follow a fibre-rich, traditional diet are likely to have a lower body weight and improved metabolic parameters than their Western-diet counterparts. The colonic effects of fibre, and more specifically the SCFA that the fermentation process produces, may play a role in maintaining energy homeostasis via their action on the G-coupled protein receptor free fatty acid receptor 2 (FFA2; formerly GPR43). In the present review, we summarise the evidence for and against the role of FFA2 in energy homeostasis circuits and the possible ways that these could be exploited therapeutically. We also propose that the decline in fibre content of the diet since the Industrial Revolution, particularly fermentable fractions, may have resulted in the FFA2-mediated circuits being under-utilised and hence play a role in the current obesity epidemic.


Asunto(s)
Regulación del Apetito/fisiología , Dieta , Carbohidratos de la Dieta , Fibras de la Dieta , Ácidos Grasos Volátiles , Receptores de Superficie Celular/fisiología , Peso Corporal , Carbohidratos de la Dieta/administración & dosificación , Fibras de la Dieta/administración & dosificación , Metabolismo Energético , Ácidos Grasos Volátiles/administración & dosificación , Fermentación , Homeostasis , Humanos , Síndrome Metabólico/prevención & control , Obesidad/epidemiología , Obesidad/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA